Panion & Bf Biotech Future Growth
Future criteria checks 0/6
We currently don't have sufficient analyst coverage to forecast growth and revenue for Panion & Bf Biotech.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
Pharmaceuticals earnings growth | 17.0% |
Revenue growth rate | n/a |
Future return on equity | n/a |
Analyst coverage | Low |
Last updated | 31 May 2024 |
Recent future growth updates
Recent updates
Is Panion & Bf Biotech (TWSE:1760) A Risky Investment?
Aug 13Here's Why Panion & Bf Biotech (TPE:1760) Has A Meaningful Debt Burden
Apr 07Is Panion & Bf Biotech Inc. (TPE:1760) A Strong Dividend Stock?
Mar 03Introducing Panion & Bf Biotech (TPE:1760), A Stock That Climbed 47% In The Last Three Years
Feb 04Are Panion & Bf Biotech Inc.'s (TPE:1760) Mixed Financials Driving The Negative Sentiment?
Jan 09Panion & Bf Biotech (TPE:1760) Has A Somewhat Strained Balance Sheet
Dec 14In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Panion & Bf Biotech has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2024 | 2,046 | N/A | 162 | 312 | 1 |
6/30/2024 | 2,009 | 101 | 93 | 295 | N/A |
3/31/2024 | 1,973 | 98 | 74 | 285 | N/A |
12/31/2023 | 1,882 | 77 | -4 | 177 | N/A |
9/30/2023 | 1,821 | -49 | -76 | 139 | N/A |
6/30/2023 | 2,008 | 22 | 63 | 280 | N/A |
3/31/2023 | 2,353 | 165 | 195 | 407 | N/A |
12/31/2022 | 2,399 | 182 | 291 | 490 | N/A |
9/30/2022 | 2,396 | 274 | 261 | 440 | N/A |
6/30/2022 | 2,263 | 256 | 250 | 408 | N/A |
3/31/2022 | 1,982 | 169 | 225 | 386 | N/A |
12/31/2021 | 1,901 | 104 | 231 | 401 | N/A |
9/30/2021 | 1,950 | 147 | 135 | 301 | N/A |
6/30/2021 | 1,807 | 84 | 61 | 223 | N/A |
3/31/2021 | 1,602 | 2 | -64 | 64 | N/A |
12/31/2020 | 1,569 | 28 | -116 | -15 | N/A |
9/30/2020 | 1,521 | 47 | 39 | 113 | N/A |
6/30/2020 | 1,485 | 68 | 20 | 113 | N/A |
3/31/2020 | 1,558 | 122 | -71 | 24 | N/A |
12/31/2019 | 1,574 | 161 | -21 | 91 | N/A |
9/30/2019 | 1,573 | 196 | -58 | 58 | N/A |
6/30/2019 | 1,555 | 200 | -52 | 31 | N/A |
3/31/2019 | 1,503 | 194 | 29 | 88 | N/A |
12/31/2018 | 1,409 | 159 | 39 | 79 | N/A |
9/30/2018 | 1,289 | 82 | 17 | 43 | N/A |
6/30/2018 | 1,272 | 86 | 53 | 76 | N/A |
3/31/2018 | 1,193 | 61 | N/A | 110 | N/A |
12/31/2017 | 1,212 | 91 | N/A | 114 | N/A |
9/30/2017 | 1,206 | 142 | N/A | 179 | N/A |
6/30/2017 | 1,140 | 131 | N/A | 211 | N/A |
3/31/2017 | 1,100 | 120 | N/A | 193 | N/A |
12/31/2016 | 1,049 | 90 | N/A | 177 | N/A |
9/30/2016 | 1,030 | 54 | N/A | 93 | N/A |
6/30/2016 | 1,101 | 70 | N/A | 58 | N/A |
3/31/2016 | 1,153 | 71 | N/A | 58 | N/A |
12/31/2015 | 1,205 | 73 | N/A | 58 | N/A |
9/30/2015 | 1,169 | 59 | N/A | 68 | N/A |
6/30/2015 | 1,133 | 46 | N/A | 79 | N/A |
3/31/2015 | 1,074 | 47 | N/A | 77 | N/A |
12/31/2014 | 1,014 | 48 | N/A | 76 | N/A |
9/30/2014 | 973 | 39 | N/A | 106 | N/A |
6/30/2014 | 932 | 30 | N/A | 137 | N/A |
3/31/2014 | 895 | 24 | N/A | 111 | N/A |
12/31/2013 | 857 | 18 | N/A | 86 | N/A |
9/30/2013 | 800 | -1 | N/A | 41 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if 1760's forecast earnings growth is above the savings rate (1%).
Earnings vs Market: Insufficient data to determine if 1760's earnings are forecast to grow faster than the TW market
High Growth Earnings: Insufficient data to determine if 1760's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: Insufficient data to determine if 1760's revenue is forecast to grow faster than the TW market.
High Growth Revenue: Insufficient data to determine if 1760's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if 1760's Return on Equity is forecast to be high in 3 years time